STOCK TITAN

Alnylam Pharmaceuticals Inc - ALNY STOCK NEWS

Welcome to our dedicated news page for Alnylam Pharmaceuticals (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alnylam Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alnylam Pharmaceuticals's position in the market.

Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. will discuss results from the KARDIA-2 Phase 2 study of zilebesiran, an RNAi therapeutic for hypertension, at the ACC Scientific Session. The webcast event will feature presentations and a Q&A session with Alnylam management and Dr. Akshay Desai.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
conferences clinical trial
-
Rhea-AI Summary
Alnylam Pharmaceuticals Launches Family Health History Road Trip Program to Encourage Health Conversations
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
none
-
Rhea-AI Summary
ByHeart, a next-generation baby nutrition company, appoints Amy Schulman as Chair of the Board, signaling a significant milestone for the company. Schulman, with extensive experience in infant formula and consumer health from Pfizer, brings valuable insights and expertise to ByHeart's leadership team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
management
Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. announced positive results from the KARDIA-2 Phase 2 study of zilebesiran, an RNAi therapeutic for hypertension. The study met primary endpoints by reducing systolic blood pressure significantly when added to standard antihypertensive treatments. The drug showed promising safety and tolerability profiles, supporting potential biannual dosing. Full study results will be presented at the 2024 American College of Cardiology Annual Scientific Session. Alnylam and Roche also initiated the KARDIA-3 Phase 2 study for patients at high cardiovascular risk with uncontrolled hypertension.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
none
-
Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. (ALNY) will be presenting at several upcoming conferences in March 2024 to provide company overviews. The presentations will be webcasted live and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
conferences
-
Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. (ALNY) achieved strong financial results in the fourth quarter and full year of 2023 with $1.24 billion in global net product revenues, marking a 39% annual growth compared to 2022. The company announced positive updates on clinical studies and FDA clearances, setting a combined net product revenue guidance of $1.4-1.5 billion for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.19%
Tags
earnings
Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. (ALNY) will report financial results for Q4 and year ending December 31, 2023, on February 15, 2024. The management will discuss results and future expectations via conference call. Participants can register online and access the call and webcast on the Investors section of the Company’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
conferences earnings
-
Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. (ALNY) CEO Yvonne Greenstreet has been named the 2024 Woman of the Year by the Healthcare Businesswomen’s Association (HBA) for her significant contributions to healthcare and the advancement of women in the workplace, announced at the J.P. Morgan Healthcare Conference. The award will be presented on May 10 in New York City. Yvonne has been with Alnylam since 2016 and has held various leadership roles, including Chief Operating Officer, President, Director, and Chief Executive Officer. Under her leadership, Alnylam has been recognized as a socially responsible company and an exceptional workplace. She has made an impact in the biopharmaceutical industry, and her accolades include being named among Fortune’s Best Workplaces for Women and inclusion in the Bloomberg Gender Equality Index.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
-
Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) achieved full year 2023 preliminary global net product revenues of $1,241 million for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO, representing 39% annual growth. The company maintained a strong balance sheet with a year-end cash and investments balance of approximately $2.4 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.93%
Tags
none
Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) will present a company overview and participate in a Q&A session at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. The presentation will include an update on unaudited fourth quarter and full year 2023 global net product revenues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
conferences
Alnylam Pharmaceuticals Inc

Nasdaq:ALNY

ALNY Rankings

ALNY Stock Data

19.44B
125.42M
0.4%
95.08%
2.41%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About ALNY

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.